Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Should You Buy?

by · The Cerbat Gem

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY – Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $28.85, but opened at $30.4199. Chugai Pharmaceutical shares last traded at $29.41, with a volume of 21,325 shares trading hands.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. UBS Group raised Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, Chugai Pharmaceutical currently has a consensus rating of “Strong Buy”.

View Our Latest Stock Report on Chugai Pharmaceutical

Chugai Pharmaceutical Stock Performance

The firm has a market capitalization of $90.90 billion, a PE ratio of 31.75 and a beta of 0.60. The business’s fifty day simple moving average is $29.19 and its 200-day simple moving average is $26.22.

Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last issued its earnings results on Thursday, January 29th. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $2.25 billion during the quarter. Chugai Pharmaceutical had a net margin of 34.47% and a return on equity of 22.00%. Sell-side analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

(Get Free Report)

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.

See Also